Estradiol regulates leptin sensitivity to control feeding via hypothalamic Cited1
Until menopause, women have a lower propensity to develop metabolic diseases than men, suggestive of a protective role for sex hormones. Although a functional synergy between central actions of estrogens and leptin has been demonstrated to protect...
González-García I, García-Clavé E, Cebrian-Serrano A et al. — Cell metabolism
Targeting the central melanocortin system for the treatment of metabolic disorders
A large body of preclinical and clinical data shows that the central melanocortin system is a promising therapeutic target for treating various metabolic disorders such as obesity and cachexia, as well as anorexia nervosa. Setmelanotide, which fun...
Sweeney P, Gimenez LE, Hernandez CC et al. — Nature reviews. Endocrinology
Pharmacologic therapeutic options for sexual dysfunction
Sexual problems are reported by up to 45% of individuals assigned female at birth. Although sexual function is a complex biopsychosocial construct, there are a number of pharmacologic treatment options aimed at addressing the changing vaginal horm...
Burton CS, Mishra K — Current opinion in obstetrics & gynecology
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for sexual activ...
Edinoff AN, Sanders NM, Lewis KB et al. — Neurology international
Pharmacotherapy for Sexual Dysfunction in Women
This review article discusses the controversy in the DSM-5 conceptualization and diagnostic criteria for female sexual dysfunction (FSD). An overview of recent studies on available treatments for hypoactive sexual desire disorder (HSDD), female se...
Lee JH, Lee JE, Harsh V et al. — Current psychiatry reports
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent
The US Food and Drug Administration (FDA) has approved two drugs for 'hypoactive sexual desire disorder' in women, flibanserin (Addyi) in 2015 and bremelanotide (Vyleesi) in 2019. In this paper we examine the outcome measures and clinical trial da...
Mintzes B, Tiefer L, Cosgrove L — Drug and therapeutics bulletin
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Nearly half of women in the United States report problems with sexual function. Many health care providers do not ask about sexual concerns during routine clinical encounters because of personal discomfort, lack of familiarity with treatment, or t...
Pettigrew JA, Novick AM — Journal of midwifery & women's health
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder
Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD). Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide, bremela...
Mayer D, Lynch SE — The Annals of pharmacotherapy
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
To evaluate the long-term safety and efficacy of bremelanotide as treatment for hypoactive sexual desire disorder in premenopausal women.
Simon JA, Kingsberg SA, Portman D et al. — Obstetrics and gynecology
Melanocortin 5 receptor signaling pathway in health and disease
Melanocortin hormone system plays a key role in maintaining the homeostasis of our body via their neuro-immune-endocrine activities and regulates a diverse array of physiological functions, including melanogenesis, inflammation, immunomodulation, ...
Xu Y, Guan X, Zhou R et al. — Cellular and molecular life sciences : CMLS